Respiratory Syncytial Virus Market
Respiratory Syncytial Virus Market Infographics

Respiratory Syncytial Virus

Respiratory syncytial virus (RSV) is a highly contagious virus that affects the respiratory system. It is classified as a member of the genus Pneumovirus in the family Paramyxoviridae. Virus particles are enveloped and pleomorphic, occurring as irregular spherical particles that are 100–350 nm in diameter and as long filamentous fibers that are 60–200 nm in diameter and 10 mm in length. 


Respiratory Syncytial Virus Epidemiology Segmentation in the 7MM


  • Total Prevalent Cases
  • Age-specific Prevalent Cases
  • Complications-specific Prevalent Cases
  • Diagnosed and Treatable Cases


Respiratory Syncytial Virus Epidemiological Insights Observed in the 7MM (2021)

The total number of incident cases of Respiratory Syncytial Virus observed in the 7MM was observed to be 5 million in the year 2021.


Respiratory Syncytial Virus Market Insight

The market size of Respiratory Syncytial Virus in the 7MM was found to be approximately USD 1,037 million in 2021.


Respiratory Syncytial Virus Emerging Drugs and Key Companies


  • MVA-BN-RSV Vaccine: Bavarian Nordic
  • RSVPREF (PF-06928316): PFIZER
  • RSVPREF3 (GSK3844766A) Vaccine: Glaxosmithkline
  • VAC 18193 (AD26.RSV.PREF): JANSSEN
  • MEDI8897 (nirsevimab): Sanofi/ Astrazeneca
  • MRNA-1345: MODERNA, and others